Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teniposide + temozolomide for recurrent high-grade glioma
ChiCTR2400087032Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teniposide and temozolomide in glioma, sponsored by West China Hospital of Sichuan University. Primary endpoints: Safety and 6-month progression-free survival rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
teniposidetemozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2400087032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087032.